Onyx continues slide, despite positive physician feedback at ASH
This article was originally published in Scrip
Shares of Onyx Pharmaceuticals continued on the downward path for the second day on 13 December, despite revealing updated positive data for its next-generation proteasome inhibitor carfilzomib at the annual meeting of the American Society of Hematology (ASH) in San Diego.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.